MHRA

MHRA

Richmond Pharmacology, the 1st Early Phase CRO to receive MHRA Standard and Supplementary Accreditation for 2 hospital based Clinical Trial Centers.Richmond Pharmacology. (RPL) have proudly received MHRA Standard and Supplementary Accreditation, a clear sign of our continued commitment to providing the highest level of subject safety on all studies conducted within our two hospital based Early Phase trial centres. RPL is unique in being the only Early Phase CRO in the UK to have two trial centres based in two acute NHS teaching hospitals.The supplementary accreditation confirms that RPL have attained the highest level of accreditation available in Europe. This permits RPL to perform the full range of Early Phase studies, including trials requiring a review of risk factors by the Expert Advisory Group (EAG).The combination of this accreditation award, our experience from conducting in excess of 400 Early Phase studies and our world-leading scientific advisory board means our sponsors can rely on RPL to continue to lead the industry in the conduct of FTIM studies, as well as other specialty areas such as TQT Studies, Japanese bridging studies, gastrointestinal studies and patient studies.For more information on the MHRA Phase I accreditation scheme visit the MHRA website.For further information on RPL's Early Phase facilities and expertise,please review our brochures.

Latest news

Clinical trials: how taking the pills can pay those bills.

April 20, 2022
The Guardian references Richmond Pharmacology in feature on reimbursement for clinical trial volunteers
Read more

Clinical trials and the patient perspective

May 6, 2022
Successful recruitment and retention of patients - an essential element to delivering clinical studies on time.
Read more

Events

The Future of Healthcare - March 2022

13:30 – 16:00, 22nd March 2022
Discover the intricacies of assessing abnormal liver functions in clinical trial volunteers and gain insights from the latest drug development trials using RNAi therapeutics.
View event